News About: Pharm. Affairs
Will the health insurance benefit of ADHD treatments for adults be extended?
Extension of the health insurance benefit of ADHD treatments for adults, which was a long-cherished wish of psychiatrists, has been discussed.
The Korean Academy of Child and Adolescent Psychiatry and the Korean Neur...
Biosimilar competition is fueled in the domestic pharmaceutical market
Competition among biosimilars will get severe in the domestic pharmaceutical market.
The market, which has been steady since the launch of Celltrion’s Remsima on November 2012, is getting fueled by patent expirations...
Registration of exclusive sales rights for Baraclude, Alimta and Thrupas
Baraclude 0.5mg, a hepatitis B drugs, Alimta, a lung cancer agent, and a generic of Thrupas, a prostatic hypertrophy treatment, have named in the list of exclusive sales rights.
The Ministry of Food and Drug Safety(M...
DAA and new agents were included in the revised hepatitis C guideline
“Research papers have been accumulated and its related data were added even while we were preparing for the revision of the guideline. That is, hepatitis C faces a new treatment paradigm.”
It was an impression of Pro...
Twynsta, Lantus and Vytorin are about to be expired in patent
This year, patent expirations of gigantic products, such as ‘Celebrex,’ an anti-inflammatory drug, ‘Cialis,’ an erectile dysfunction treatment, and ‘Baraclude,’ a hepatitis B treatment, have triggered fierce generic c...
Basaglar, a Lantus biosimilar, enters the domestic market
Basaglar, a biosimilar product of Lantus(Insulin Glargine), a Sanofi’s basal insulin treatment, will enter the domestic diabetic treatment market.
Lilly Korea, as of the 25th, acquired approval of Basaglar Kwikpen an...
Unconquerable fortress of Januvia substance patent defeats domestic pharmaceuticals
The wall of substance patent was sturdy. Like ‘Baraclude,’ ‘Januvia,’ a diabetic treatment, succeeded in defending its substance patent from other challenges. The nullity request against the extension of the term of t...
Teva, the patent suit expert, achieves the first ‘winning’ against AZ in Korea
Teva, which grew its body through patent lawsuits in the U.S., announced the first ‘winning’ of a lawsuit in Korea.
Teva-Handok, jointly established in Korea by Teva and Handok, succeeded in avoiding 3 formulation pa...
Doctors said, “The current trend is oral rheumatoid arthritis treatment”
“Needs of patients are pretty high for oral rheumatoid arthritis treatments. As long as the safety data of oral antirheumatic drugs is secured, there is a high chance for them to be a secondary rheumatoid arthritis tr...
Prescriptions of risedronate sodium doubled up while alendronate sodium dropped
A research was revealed to study an aspect of prescription changes among bisophosphonate-type single drugs which have led the osteoporosis treatment market.
While a prescription rate of risedronate(original: Actonel)...
